Gilead Sciences, Inc. $GILD Stock Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% during the third quarter, HoldingsChannel.com reports. The fund owned 151,740 shares of the biopharmaceutical company’s stock after selling 4,196 shares during the quarter. State of Alaska Department of Revenue’s holdings in Gilead Sciences were worth $22,616,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of GILD. Davidson Trust Co. lifted its position in Gilead Sciences by 4.1% in the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 74 shares during the period. Grove Bank & Trust lifted its position in shares of Gilead Sciences by 1.2% in the 3rd quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock valued at $946,000 after acquiring an additional 74 shares in the last quarter. Financial Connections Group Inc. boosted its stake in Gilead Sciences by 30.2% in the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 76 shares during the period. Wilkerson Advisory Group LLC boosted its stake in Gilead Sciences by 54.2% in the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 78 shares during the period. Finally, Balboa Wealth Partners boosted its stake in Gilead Sciences by 2.7% in the 1st quarter. Balboa Wealth Partners now owns 3,057 shares of the biopharmaceutical company’s stock worth $426,000 after purchasing an additional 79 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD traded up $5.80 during midday trading on Thursday, hitting $159.34. The company had a trading volume of 3,193,259 shares, compared to its average volume of 6,790,415. The firm has a fifty day simple moving average of $146.20 and a two-hundred day simple moving average of $136.99. Gilead Sciences, Inc. has a fifty-two week low of $114.02 and a fifty-two week high of $160.51. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock has a market cap of $197.57 billion, a price-to-earnings ratio of -59.74 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.01 earnings per share. Equities analysts forecast that Gilead Sciences, Inc. will post -0.47 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were paid a dividend of $0.82 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. Gilead Sciences’s payout ratio is currently -122.85%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Truist Financial increased their target price on Gilead Sciences from $150.00 to $158.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Morgan Stanley dropped their target price on Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating on the stock in a report on Wednesday, October 7th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $159.33.

Insider Transactions at Gilead Sciences

In other news, Director Anthony Welters sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the transaction, the director directly owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $144.22, for a total transaction of $432,660.00. Following the completion of the sale, the insider directly owned 116,684 shares in the company, valued at approximately $16,828,166.48. The trade was a 2.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 105,000 shares of company stock worth $14,940,540. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New solid-tumor cancer partnership expands Gilead’s pipeline. Gilead and Vir will discover and develop three dual-masked PRO-XTEN® T-cell engager candidates for solid tumors. Gilead receives exclusive development and commercialization rights, giving it access to Vir’s immunology and antibody-engineering technology. The deal strengthens Gilead’s longer-term oncology opportunity, although the programs remain in development. Vir Biotechnology and Gilead collaborate on novel cancer therapeutics
• Positive Sentiment: Analyst sentiment includes bullish views. Recent coverage identifies Gilead among healthcare stocks attracting positive analyst attention, which may reinforce investor confidence in the company’s earnings, dividend profile and pipeline prospects. Analysts Are Bullish on These Healthcare Stocks
• Positive Sentiment: Recent trading momentum is favorable. GILD has moved above its February peak and remains well above its 50-day and 200-day moving averages. Its latest reported quarterly results also exceeded consensus expectations for earnings and revenue, supporting the stock’s fundamental momentum. Gilead Sciences Clears Its February High
• Neutral Sentiment: Investor attention has increased, but the outlook is not uniformly bullish. Zacks highlighted elevated interest in Gilead, while separate coverage noted conflicting analyst sentiment. This may increase trading activity without establishing a clear consensus on valuation or future performance. Gilead Sciences Is Attracting Investor Attention

Gilead Sciences Company Profile

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.